NASDAQ:MTSR Metsera (MTSR) Stock Price, News & Analysis $25.38 -1.49 (-5.55%) As of 06/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Metsera Stock (NASDAQ:MTSR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Metsera alerts:Sign Up Key Stats Today's Range$24.13▼$26.5850-Day Range$13.08▼$35.1052-Week Range$12.30▼$37.99Volume1.13 million shsAverage Volume1.00 million shsMarket Capitalization$2.67 billionP/E RatioN/ADividend YieldN/APrice Target$50.00Consensus RatingBuy Company OverviewMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Read More… Receive MTSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metsera and its competitors with MarketBeat's FREE daily newsletter. Email Address MTSR Stock News HeadlinesCantor Fitzgerald Forecasts Metsera FY2026 EarningsJune 13, 2025 | americanbankingnews.comPromising Results Of Amylin Analogs In Obesity: Metsera Case ReviewJune 12, 2025 | seekingalpha.comWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.June 18, 2025 | Crypto Swap Profits (Ad)Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 ResultsJune 11, 2025 | msn.comMetsera (NASDAQ:MTSR) Shares Gap Up Following Analyst UpgradeJune 11, 2025 | americanbankingnews.comMetsera extends gains after early-stage trial data for obesity therapyJune 10, 2025 | msn.comMetsera Clears Key Benchmark, Hitting 80-Plus RS RatingJune 10, 2025 | msn.comMetsera to Present at Goldman Sachs 46th Annual Global Healthcare ConferenceJune 10, 2025 | globenewswire.comSee More Headlines MTSR Stock Analysis - Frequently Asked Questions How have MTSR shares performed this year? Metsera's stock was trading at $29.50 on January 1st, 2025. Since then, MTSR stock has decreased by 14.0% and is now trading at $25.38. View the best growth stocks for 2025 here. How were Metsera's earnings last quarter? Metsera Inc. (NASDAQ:MTSR) announced its quarterly earnings data on Monday, May, 12th. The company reported ($1.03) earnings per share for the quarter. When did Metsera IPO? Metsera (MTSR) raised $275 million in an initial public offering (IPO) on Friday, January 31st 2025. The company issued 15,277,778 shares at $18.00 per share. When does Metsera's lock-up period expire? Metsera's lock-up period expires on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its public offering on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the expiration of Metsera's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. Who are Metsera's major shareholders? Top institutional investors of Metsera include Alphabet Inc. (4.72%), T. Rowe Price Investment Management Inc. (2.75%), Wellington Management Group LLP (2.29%) and Alpha Wave Global LP (2.27%). How do I buy shares of Metsera? Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2025Today6/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MTSR Previous SymbolNASDAQ:MTSR CIK2040807 WebN/A Phone(212) 784-6595FaxN/AEmployees81Year FoundedN/APrice Target and Rating Average Stock Price Target$50.00 High Stock Price Target$62.00 Low Stock Price Target$38.00 Potential Upside/Downside+97.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares105,056,000Free FloatN/AMarket Cap$2.67 billion OptionableN/A BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:MTSR) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhat 99% of investors are missing about Chinese AIChinese AI chatbot DeepSeek's release put the spotlight on AI and turned the tech world on its head. But 99...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.